Rigel Pharmaceuticals (NASDAQ: RIGL) is one of 288 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Rigel Pharmaceuticals to related companies based on the strength of its risk, earnings, profitability, analyst recommendations, dividends, institutional ownership and valuation.
This is a breakdown of current ratings and target prices for Rigel Pharmaceuticals and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rigel Pharmaceuticals Competitors||1380||4480||12320||312||2.63|
Rigel Pharmaceuticals presently has a consensus target price of $6.75, indicating a potential upside of 182.43%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.37%. Given Rigel Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Rigel Pharmaceuticals is more favorable than its peers.
Risk & Volatility
Rigel Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals’ peers have a beta of 6.57, indicating that their average stock price is 557% more volatile than the S&P 500.
Valuation and Earnings
This table compares Rigel Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Rigel Pharmaceuticals||$10.34 million||-$67.71 million||-3.46|
|Rigel Pharmaceuticals Competitors||$464.94 million||$167.77 million||-6.75|
Rigel Pharmaceuticals’ peers have higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares Rigel Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rigel Pharmaceuticals Competitors||-4,766.74%||-354.83%||-43.39%|
Institutional & Insider Ownership
88.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 51.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.2% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The Company’s clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted a new drug application (NDA) to the United States food and drug administration (FDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). In addition, the Company has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics. The Company is engaged in conducting research in the disease areas of inflammation/immunology and muscle wasting/muscle endurance.
Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.